To analyse the relation between overweight, obesity and fat distribution with I/D polymorphism of the angiotensinconverting enzyme (ACE) gene and its association with coronary heart disease (CHD). DESIGN: Cross-sectional, case-control study. SUBJECTS: A total of 185 cases (141 males) who had suffered at least one episode of CHD and 182 controls (127 males). MEASUREMENTS: Body mass index, waist circumference, blood pressure, plasma total cholesterol, triglycerides, HDL cholestrol and fasting glucose were measured with standard methods, genotyping the I/D polymorphism of ACE gene. RESULTS: Obesity and abdominal fat deposit are associated with CHD in women, but not independently. We have found an association between obesity and abdominal fat deposit with the ACE gene I/D polymorphism in subjects with CHD. Subjects with CHD and DD or ID genotypes have significantly higher prevalence of obesity and abdominal fat deposit and higher values of weight and waist circumference. In addition, the DD and ID genotypes increased crude OR of obesity. The DD and ID genotypes of the ACE gene I/D polymorphism and BMI are independently associated with CHD. CONCLUSION: There is a relation between the type and grade of obesity with the genotypes of the ACE gene I/D polymorphism in subjects with CHD.
Introduction
The measures of obesity and weight gain are clearly related to the risk of coronary heart disease (CHD) and to total mortality. 1, 2 The question is whether or not obesity is an independent factor of cardiovascular risk, or this association is established due to the effects that obesity has on the cardiovascular risk factors (high blood pressure, hypercholesterolaemia, diabetes).
The different epidemiological studies give contradictory results. Accordingly, in some studies, it has been demonstrated that body mass index (BMI) predicts CHD, 3 although this association is not independent in other studies. 4, 5 Therefore, it seems that obesity is in fact an important determinant of cardiovascular risk factors. 6 The angiotensin-converting enzyme (ACE) gene I/D polymorphism involves the presence (I) or absence (D) of a fragment of 287 base pairs in intron 16. 7 The homozygotes for the allele D show higher serum values of the immunoreagent ACE, almost twice the values shown by the homozygotes for allele I. One of the main roles of the serum ACE is the production of angiotensin II, a potent vasoconstrictor that also affects the vascular smooth muscular cells and myocardio-cytes, increases the synthesis of the extracellular collagen matrix and inhibits physiological fibrinolysis, all of these being mechanisms related to the pathogeny of CHD. 8 Cambien et al 9 were the first investigators to demonstrate the association of the ACE gene I/D polymorphism with acute myocardial infarction (AMI). Compared with controls, in their case-control study, the prevalence of the genotype DD was significantly higher in the group with AMI (32% compared to 28%), which gave an odds ratio of 1.34. On studying the risk of AMI in a low-risk subgroup, it was found that the prevalence of the genotype DD was greater than that for the complete group with an odds ratio (OR) of 3.2. These findings have also been shown in other populations, even in prospective studies. 10, 11 However, not all studies have demonstrated this association. 12, 13 There are few studies that have investigated the association between BMI, ACE gene I/D polymorphism and CHD. 10, 13 In Mediterranean populations in Southern Europe with a low incidence and prevalence of CHD, the commented relation has not been studied. On the other hand, obesity is caused by the interaction of genetic and environmental factors related to lifestyle. 14 It is likely that minor genes implicated in the adipogenesis process, or in the regulation of fat tissue metabolism, can lead to susceptibility to obesity. 14 The genes that codify the components of the renin angiotensin system (RAS) are probably found within this group, but little attention has been paid to these. There is enough experimental and clinical evidence to consider that polymorphisms of the RAS genes, such as the ACE gene I/D polymorphism, could be minor candidate genes for obesity. Accordingly, the presence of angiotensinogen, of the ACE and the type 1 and 2 receptors for angiotensin II has been shown in human adipose tissue. 15 Therefore, our main objective is to analyse the relation between overweight, obesity and fat distribution with the genotype of the ACE gene I/D polymorphism and, secondary, its association with CHD in a Mediterranean population in Southern Europe with a low prevalence of CHD. 23 
Methods
We carried out a retrospective, observational study of cases and controls in an adult population of both sexes, aged between 35 and 79 y.
Included in the study were 185 cases (141 males) who had suffered at least one episode of CHD, defined by AMI diagnosed according to the World Health Organization criteria (compatible clinical history, enzymatic movement and electrocardiographic changes) or 'angina pectoris' with positive effort test. Subjects were excluded if the time between the incidence of CHD and participation in the study was less than 3 months.
Also included were 182 controls (127 males), selected on the basis of absence of personal or family history of CHD, no signs of chronic illness and a normal analysis (haemogram, general chemistry and thyroid function). This control group should have no cardiovascular risk factors, or have only one of the following: high blood pressure (BP Z140/90 mmHg or be undergoing treatment), tobacco habit, diabetes mellitus (fasting glycaemia Z126 mg/dl or undergoing hypoglycaemic treatment) or dyslipaemia (fasting total cholesterol and/ or triglycerides Z200 mg/dl or undergoing hypolipidaemic treatment). Type or grade of obesity was not an exclusion criterion.
All the subjects were selected by consecutive sampling from a primary care outpatient clinic in the metropolitan area of Valencia, complying with the criteria of voluntary participation and the inclusion and exclusion criteria previously mentioned. The cases and controls come from the same target population.
The study was approved by the ethical committee of our hospital.
Determination of clinical parameters
Once we had obtained consent from the subjects, and after informing them of the objectives of the study, an anamnesis and physical examination were carried out on each of them by the same investigator. A complete anthropometric study was carried out on each of the participants (weight, height, BMI, waist circumference, subscapular and triceps skin folds) and blood pressure reading (after 5 min of rest, with mercury sphygmomanometer), a general biochemical determination and a genetic study were carried out.
Weight in kg was determined using a standard beam-balance scale, and with the patient barefoot and wearing light indoor clothing. Height in centimetres was measured using a meter rule built in to the scale. BMI was calculated by dividing weight in kg by height in meters squared. Waist circumference was measured with a flexible measuring tape, taking as a reference the midway line between the costal inferior border and the iliac crest. The triceps skin folds and subscapular skin folds were measured in mm as an average of three measurements taken with a Holtain calibrator at the established standardized points. 24 ACE gene I/D polymorphism, adiposity and coronary heart disease C Riera-Fortuny et al
Being overweight was defined as BMI between 27 and 30 kg/m 2 , obesity as BMI Z30 kg/m 2 and abdominal fat deposit as having a waist circumference of Z102 cm in males and Z88 cm in females. These definition criteria have been validated and accepted by numerous consensuses. 25 
Laboratory methods
The blood samples were taken following a 12-h, overnight period of fasting. The plasma was separated immediately (3000 rpm for 10 min, at 41C). The samples were processed immediately or during the following 10 days, conserving them at À201C. Cholesterol, triglycerides and glucose were determined using automated enzymatic methods (autoanalyzer Roche/Hitachi 747). HDL cholesterol (HDL-c) was measured after precipitation of apo B-containing particles with dextran sulphate -CI 2 Mg.
Genetic study
The extraction of DNA from the leucocytes was performed using a standardized method. 26 The sequence of the ACE gene I/D polymorphism was determined in all the individuals using the polymerase chain reaction (PCR) technique, following procedures and using oligonucleotides already described by Rigat et al. 27 This technique is widely validated and available, although the amplification conditions were optimized for the enzyme used in our laboratory in order to obtain an equal amount of each of the allele in the heterozygote individuals, thus minimizing the possibility of introducing an excess of allele D. In the case of dubious cases (clear bands), the PCR was repeated and the products of this were analysed using agarose gel electrophoresis.
Statistical analysis
Statistical analysis was performed by using SPSS statistical software, version 10.0 (SPSS, Inc., Chicago, IL, USA).
The size of the sample was calculated as a function of the prevalence of the genotype DD in the control population (27%, average of the prevalence of Caucasian countries) and the OR of CHD associated with this genotype (1.9).
For the descriptive analysis, in the case of quantitative variables, we used measures of central tendencies and normal dispersion: average, standard deviation (s.d.) and the 95% confidence interval.
The different genotypes of the ACE gene I/D polymorphism categorized the subjects into three groups (II, ID, DD).
To compare the averages of the quantitative variables, the one-way ANOVA test was used. To compare the proportions, the chi-squared (w 2 ) test was used. To estimate the risk of the different factors, a logistic regression analysis was carried out, taking the presence of CHD as the dependent variable. The OR and confidence interval (CI) of 95% were estimated in this way.
Results
The general characteristics of the case and control groups divided by gender are shown in Table 1 . As expected from the selection criteria of the control group, there are statistically significant differences in the prevalence of classical cardiovascular risk factors (hypertension, diabetes and dyslipaemia) (data not shown) and values of blood pressure, triglycerides, HDL-c and glycaemia between both groups. These differences were maintained between genders.
Anthropometric parameters and prevalence of CHD The anthropometric parameters of the case and control groups divided by gender are shown in Table 2 . Considering the group as a whole, we found statistically significant differences between cases and controls in the BMI, waist and subscapular skin folds, which were maintained in the analysis of the women. In the group of males, we only found statistically significant differences between the cases and controls in the triceps and subscapular skin folds.
The multivariate analysis adjusted for age and gender shows that the BMI (OR 2.22, 95% CI 1.4-3.6), and weakly 
Association of the ACE gene I/D polymorphism with overweight, obesity and abdominal fat deposit
In the group with CHD, we found that the genotype II is associated with a statistical significant lower prevalence of obesity (genotype II 11% vs ID 43% and DD 35%, Po0.05) and greater prevalence of overweight (genotype II 33% vs ID 6% and DD 15% P ¼ 0.003), while having a genotype with the presence of some allele D is associated with a greater prevalence of obesity and lower prevalence of overweight. Additionally, the average weight values were significantly higher in subjects with CHD carriers of an allele D (genotype DD 77.9711.3 and ID 82.2713.9 vs genotype II 74.7711.6 kg, P ¼ 0.021).
Abdominal fat deposit is less prevalent in the case group with genotype II (genotype II 33% vs ID 59% and DD 35%, Po0.05). Also, the average waist circumference values were significantly higher in the subjects with CHD carriers of an allele D (genotype DD 99.9711.2 and ID 103.1711.5 vs genotype II 96.6712.3 cm, P ¼ 0.044).
Accordingly, the genotype DD raises the crude OR for obesity from 2.22 (95% CI 1.4-3.6) to 2.67 (95% CI 1.54-5.34) and the genotype II lowers the OR to 0.24 (95% CI 0.05-1.15), thus having a protecting effect.
These findings were not found in the control group (data not shown).
We did not find statistically significant differences in the average values of the triceps and subscapular skin folds between the different groups divided by genotypes.
We did not find that the genotypes of the ACE gene I/D polymorphism are associated with high blood pressure, diabetes or dyslipaemia.
Association between the ACE gene I/D polymorphism and CHD
The prevalence of the genotypes of the ACE gene I/D polymorphism in the group of cases and controls is shown in Table 3 . All polymorphisms are in Hardy-Weinberg equilibrium.
We found statistically significant differences when comparing the prevalence of the genotype II between the cases and controls (10% compared to 18%, P ¼ 0.028). Furthermore, the prevalence of the sum of genotypes DD and ID is significantly greater in the group of cases (90% compared to 82%, P ¼ 0.028). Taking the genotype II as a reference, the genotypes DD and ID are associated with CHD with an OR of 1.98 (95% CI 1.07-3.67) and quite separately, the genotype DD is associated with CHD with an OR of 2.1 (95% CI 1.08-4.07).
The multivariate analysis through logistic regression, adjusted for age and gender, and taking as independent variables the genotype I/D and cardiovascular risk factors (arterial hypertension, dyslipaemia, obesity, diabetes and smoking habit), shows that the genotypes DD and ID are independently associated with CHD with an OR of 1.85 (95% CI 1.05-3.25). ACE gene I/D polymorphism, adiposity and coronary heart disease C Riera-Fortuny et al
Association of anthropometric parameters and ACE gene I/D genotype with CHD
The multivariate analysis through logistic regression, adjusted for age and gender, and taking as a dependent variable the presence of CHD and as independent variables the genotype I/D and the different anthropometric parameters studied (BMI, waist circumference, subscapular skin folds and quantity of body fat), shows that only the BMI (OR 2.63, 95% CI 1.19-5.82) and the subscapular skin folds (OR 1.09, 95% CI 1.03-1.14) are independently and significantly associated with CHD.
Discussion
Firstly, in our case-control study, we have found that obesity, abdominal fat deposit and subscapular folds are associated with CHD in a population of Southern Europe with low prevalence and incidence of CHD. But this association is not independent when introducing the classic cardiovascular risk factors. These findings are in accordance with those found by different investigation groups 4, 5 in other populations. In these studies, an association between BMI or greater waist hip ratio or abdominal circumference and the CHD was found, but this was not independent. Therefore, in our population as well, the grade and type of obesity would in fact be important determinants of the cardiovascular risk factors. Accordingly, there is sufficient experimental and clinical evidence that shows that adiposity, fundamentally visceral, alters the hydrocarbonate and lipidic metabolism and is associated with higher blood pressure levels, all of these being known as independent cardiovascular risk factors. 28 Furthermore, the role of adiposity as an etiological factor of glucose intolerance, diabetes and dyslipaemia has been shown in prospective studies. 29 In our study, carried out in a population of low risk of CHD, the genotypes DD and ID are independently associated with CHD. As we have commented, the presence of allele D would increase the serum concentrations of ACE 7 and this would increase the production of angiotensin II with its detrimental vascular effects. 8 It is thought that because of this mechanism the genotype DD of the ACE gene I/D polymorphism is associated with CHD. However, not all studies in populations of low risk of CHD such as ours find this association. 30 This apparent contradiction could be due to methodological problems. Therefore, it is necessary to promote more prospective studies in Mediterranean populations in Southern Europe to analyse the causal association between ACE gene I/D polymorphism and CHD.
On the other hand, our cross-sectional study demonstrates an association between the genotypes DD and ID of the ACE gene and adiposity in subjects with CHD, but not in control subjects. Furthermore, the subjects with CHD carriers of the genotype II show lower weight, waist circumference and prevalence of fat deposit and higher prevalence of BMI o27 kg/m 2 . Recently, another study in an Italian population of Southern Europe has shown an association of the genotype DD with being overweight, abdominal fat deposit and the weight gain in males of a control population. 22 There is sufficient clinical and experimental evidence that shows a relation between the RAS and the development of adipose tissue. 31 In vitro, it has been demonstrated that angiotensin II stimulates the prostacylin in the adipocytes, which stimulates the differentiation of the precursors of adipocytes. 17, 18 In addition, the adipose tissue contains the main components of RAS: angiotensin, ACE, angiotensin I and angiotensin II receptors 15, 16 with differential expression if the subcutaneous or omental fat is studied. How to explain the association of the genotype DD and ID with obesity and abdominal fat deposit in subjects with CHD, and not in controls: On the one hand, the minor genes for obesity, as in the case of the ACE gene, would have a relatively small effect on the development of obesity. It would require time and the concurrence of other genetic and environmental factors for complete development. Accordingly, in the study by Strazzullo et al, 22 the genotype DD is associated with being overweight and abdominal fat deposit (defined by waist circumference), but not with obesity. In this study, the difference in the weight gain associated with the genotype DD was 1.45 kg (95% CI 0.12-2.78 kg) and the relative risk of being overweight was 2.34 (95% CI 1.32-4.15) in the subgroup of subjects with 20 y of monitoring.
On the other hand, it seems that there exists a differential expression of the components of RAS in adipose tissue depending on its location. 32 Thus, this expression would be greater in omental tissue and would probably be related to the metabolic changes found in the insulin resistance (IR) syndrome. 32 The ACE gene I/D polymorphism genotypes have recently been linked with elements of IR syndrome in patients with premature CHD 33, 34 and in the Chinese diabetes type 2 population.
34
Our cross-sectional study includes a group with CHD with higher prevalence of obesity and abdominal fat distribution associated with metabolic risk factors of CHD, common of IR. Therefore, if we think that the ACE gene is a minor gene for obesity, its expression is higher in omental fat and it is related to metabolic factors of cardiovascular risk, it would be logical to find in a cross-sectional study a greater association between the genotype DD and ID with the type and grade of obesity in a group with CHD. We should remember that the control group includes subjects without any or with only one classical cardiovascular risk factor. Therefore, in the group of controls the effect of the genotype should be diluted.
Our cross-sectional study does not prove a causal relation between the ACE gene I/D polymorphism, adiposity and prevalence of CHD, but there is sufficient clinical and experimental evidence to suggest that this gene could have a causal role. We hypothesized that the D allele will predispose to obesity and abdominal fat deposits and that ACE gene I/D polymorphism, adiposity and coronary heart disease C Riera-Fortuny et al this subject will accumulate more classical CHD factors and therefore a higher incidence of CHD. Firstly, as previously commented, all the components of RAS are found in the human adipose tissue with a differential expression depending on whether it corresponds to subcutaneous or omental fat tissue. 32 The angiotensin whose synthesis comes regulated by the ACE has an important role in the differentiation of adipose tissue 17, 18 and, as we have commented, it has effects related to the pathogeny of CHD. 8 Secondly, there are sufficient clinical studies that find an association between the serum components of RAS and BMI. Furthermore, in the study by Strazzullo et al 22 in the males monitored for 20 y, the increase in weight and the risk of being overweight are related to the genotype DD of the ACE gene.
Our study also demonstrates that the DD and ID genotype and BMI were independently associated with CHD. Therefore, our results and all of those contributed by other investigation groups could indirectly suggest that the genotype DD contributes as a genetic factor to the development of obesity (overcoat in abdominal fat deposit) and this relation would be overexpressed in subjects with CHD.
To summarize, in a population of Southern Europe with a low prevalence and incidence of CHD, obesity and abdominal fat deposit are not independently associated with the CHD. We have found an association of ACE gene I/D polymorphism with obesity and abdominal fat deposit in subjects with CHD. In addition, the DD and ID genotypes of ACE gene and BMI were independently associated with CHD.
To conclude, there is an association between the type and grade of obesity with the genotypes of the ACE gene I/D polymorphism in subjects with CHD, and both factors are independently associated with CHD. It is necessary to carry out prospective studies in order to confirm this hypothesis.
